MDNAF — Medicenna Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Medicenna Announces Submission Of Clinical Trial Application In Australia For A Phase 1/2 Study Of MDNA11
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
Brief: Medicenna Announces Peer-Reviewed Publication Of Clinical Data From Phase 2B Trial Evaluating MDNA55
Brief: Medicenna Announces Preclinical Data On Mdna11 At The Cytokine-Based Cancer Immunotherapies Summit
Brief: Medicenna Therapeutics Says Net Loss For Quarter Ended December 31, 2020 Was C$5.3 Million
Brief: Medicenna Therapeutics Corp - Entered Into A Sales Agreement With Svb Leerink
Brief: Medicenna Presents Promising Preclinical Data On IL-2 And IL-13 Superkines At The EORTC-NCI-AACR Annual Meeting
Brief: Medicenna Presents Late Breaking Abstract Updating Results From Phase 2B Recurrent GBM Trial
Brief: Medicenna Provides MDNA55 Rgbm Clinical Program Update Following Positive End Of Phase 2 Meeting With The U.S. Food And Drug Administration
Brief: Medicenna To Commence Trading On Nasdaq
Brief: Medicenna Reports First Quarter Fiscal 2021 Financial Results And Operational Highlights
Brief: Medicenna Updates Efficacy Results From Phase 2B Recurrent Gbm Trial At Asco 2020
Brief: Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1
Brief: Medicenna To Present Pre-clinical Data On MDNA19
Brief: Medicenna Announces Pricing Of $35 Million Overnight Marketed Offering Of Common Shares
Brief: Medicenna Therapeutics QTRLY Loss Per Share $0.07
Brief: Medicenna Reports Results From Recurrent Glioblastoma Trial When Compared To An Eligibility-Matched Control Arm
Brief: Medicenna Presents Additional Phase 2B Clinical Data At Glioblastoma Drug Development Summit
Brief: Medicenna Therapeutics Announces Positive Results On Drug Distribution From Phase 2B Clinical Trial Of MDNA55